Cargando...
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments
The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK (anaplastic lymphoma kinase) was revolutionized by crizotinib, a small molecule inhibitor of ALK, ROS1 and MET. Unfortunately, the disease progressed within the first 12 months in...
Gardado en:
| Publicado en: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4699265/ https://ncbi.nlm.nih.gov/pubmed/26753004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834015617355 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|